Table 3.

Multivariate Cox regression analysis of risk factors after AML-type primary therapy

ParameterHazard ratioLCLUCLP
WBC 1.005 1.002 1.007 .002 
CD19 3.17 1.39 7.21 .006 
ParameterHazard ratioLCLUCLP
WBC 1.005 1.002 1.007 .002 
CD19 3.17 1.39 7.21 .006 

Results of the multivariate Cox regression analysis of EFS in cases without evidence of a preexisting genetic disease or the specified gene fusions (ETV6/RUNX1, RUNX1/RUNX1T1, PML/RARA, or BCR/ABL1) primarily treated with AML-type therapy. For treatment type, 11 factors that withstood the univariate prescreening (listed in “Patients and methods”) were included in the model.